Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 6/20 | 0.60 |
| ▸ | DOT1L | Q8TEK3 | 5/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | GNMT | Q14749 | 1/20 | 0.49 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536759 | 0.93 | AHCY (0.52) | AHCYDOT1LHIF1ATMEM97SIGMAR1 | |
| SCHEMBL2780483 | 0.91 | AHCY (0.49) | AHCYDOT1LADORA1 | |
| SCHEMBL8362057 | 0.89 | ADORA3 (0.50) | AHCYDOT1LHIF1ATMEM97SIGMAR1 | |
| SCHEMBL940909 | 0.87 | ADORA3 (0.49) | AHCYDOT1LHIF1ATMEM97SIGMAR1 | |
| SCHEMBL3292851 | 0.86 | AHCY (0.52) | AHCYDOT1LHIF1ATMEM97SIGMAR1 | |
| SCHEMBL8982539 | 0.84 | AHCY (0.65) | AHCYDOT1LHIF1ATMEM97SIGMAR1 | |
| SCHEMBL4192540 | 0.83 | AHCY (0.66) | AHCYDOT1LHIF1ATMEM97SIGMAR1 | |
| SCHEMBL6692383 | 0.81 | AHCY (0.54) | AHCYDOT1LHIF1ATMEM97SIGMAR1 | |
| SCHEMBL1972796 | 0.81 | AHCY (0.63) | AHCYDOT1LHIF1ATMEM97SIGMAR1 | |
| SCHEMBL8461385 | 0.80 | AHCY (0.51) | AHCYDOT1LADORA1CARM1GNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205671-A1 | Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury | EMORY UNIVERSITY | 2006-09-14 | — | — | US | claimed |
| EP-1638579-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2005003150-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2005-01-13 | — | — | WO | claimed |
| US-20100272711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | THOMAS JEFFERSON UNIVERSITY (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100047798-A1 | ADENOSINE A1 AND A3 RECEPTOR GENE SEQUENCE VARIATIONS FOR PREDICTING DISEASE OUTCOME AND TREATMENT OUTCOME | THOMAS JEFFERSON UNIVERSITY (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2009076580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | THOMAS JEFFERSON UNIVERSITY (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008058238-A2 | ADENOSINE A1 AND A3 RECEPTOR GENE SEQUENCE VARIATIONS FOR PREDICTING DISEASE OUTCOME AND TREATMENT OUTCOME | THOMAS JEFFERSON UNIVERSITY (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20060205671-A1 | Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury | EMORY UNIVERSITY | 2006-09-14 | — | — | US | disclosed |
| EP-1638579-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005003150-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047798-A1 | ADENOSINE A1 AND A3 RECEPTOR GENE SEQUENCE VARIATIONS FOR PREDICTING DISEASE OUTCOME AND TREATMENT OUTCOME | ADORA3, ADORA1, ADORA2A | AHCY 342/4885DOT1L 4831/4885HIF1A 417/4885 |
| US-20100272711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | ADORA2A, ADORA1, ADORA2B | AHCY 322/4885DOT1L 4882/4885HIF1A 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.